Monoclonal antibody defines CA 19-9 in pancreatic juices and sera. Issue 5 (May 1985)

• Record Type: Journal Article
• Authors: Schmiegel, W H; Kreiker, C; Eberl, W; Arndt, R; Classen, M; Greten, H; Jessen, K; Kalthoff, H; Soehendra, N; Thiele, H G
• Is Part Of: Gut. Volume 26:Issue 5(1985)
• Page Start: 456
• Page End: 460
• Publication Date: 1985-05
• Subjects: Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gut.26.5.456
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : In a retrospective study pancreatic juice samples (n = 213) and corresponding serum samples (n = 110) were assayed for their concentration of monoclonal antibody defined CA 19-9/GICA (gastrointestinal cancer associated antigen). Serum CA 19-9 values were found to be good diagnostic and discriminating markers for pancreatic disorders and were raised (greater than 50 u/ml) in more than 80% of the pancreatic cancer patients compared to 8.5% of the pancreatitis group and none of the control group. In contrast pancreatic juice CA 19-9 values showed a considerable overlap between groups. On the basis of recent molecular data on the monoclonal antibody 19-9 defined antigen(s)--that is, monosialoganglioside, mucin--it is proposed that the discrepancies between serum and pancreatic juice findings are due to a specific undirected endocrine release of the mucin into sera in pancreatic tumour patients while in pancreatic juices of all diagnostic groups high CA 19-9 activities are either owing to coexistence of glycolipid and mucin or that the latter is a physiologically exocrine product.